What is the current market size?

The Cutting Biopsy System For Breast Lesion market size was valued at USD 1.2 billion in 2023, driven by rising breast cancer prevalence and advanced diagnostic needs.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, fueled by technological innovations and increased healthcare expenditures.

What challenges does the market face?

High device costs, limited reimbursement coverage, and stringent regulatory requirements hinder market expansion in developing regions.

Which regions are leading the market?

North America dominates the market, while Asia-Pacific shows the highest growth due to improving healthcare infrastructure and diagnostic accessibility.

Who are the top companies in this market?

Leading players include Boston Scientific, Medtronic, and Hologic, which focus on R&D and strategic partnerships to maintain market share.

What future opportunities exist?

Future opportunities lie in AI-integrated systems, portable devices for rural areas, and expanding applications in early-stage lesion detection.

How is technology shaping the market?

Technological advancements like real-time imaging, robotic precision, and automated tissue sampling enhance diagnostic accuracy and patient outcomes.

What is the regulatory landscape?

Regulatory approvals by bodies like the FDA and EMA are critical, with emphasis on safety, efficacy, and compliance to ensure market entry and acceptance.

Cutting Biopsy System For Breast Lesion - Strategic Insights: Analysis 2025 and Forecasts 2033

Cutting Biopsy System For Breast Lesion by Application (Malignant Breast Tumors, Benign Breast Tumors), by Types (Full Cut, Half Cut), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Cutting Biopsy System For Breast Lesion Market Size | CAGR 7.8 Forecast 2033

Cutting Biopsy System For Breast Lesion - Strategic Insights: Analysis 2025 and Forecasts 2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Cutting Biopsy System For Breast Lesion Market Overview

The Cutting Biopsy System For Breast Lesion market encompasses devices designed for minimally invasive diagnosis and treatment of breast abnormalities, driven by rising breast cancer incidence and demand for precision diagnostics. This market is critical in enabling early detection and reducing patient recovery times, aligning with global healthcare priorities. The Cutting Biopsy System For Breast Lesion market size was estimated at $385 million in 2025, reflecting robust growth outlook with a projected 7.2% CAGR through 2033, reaching $780 million by 2033. Macro drivers include advancements in imaging-guided biopsy technologies, regulatory support for non-invasive procedures, and growing awareness of early breast cancer detection. North America dominates the market forecast due to established healthcare infrastructure, while Asia-Pacific is the fastest-growing region, fueled by rising diagnostic investments and urbanization.

Loading chart…

Key forces shaping the Cutting Biopsy System For Breast Lesion industry expansion include technological innovation in real-time imaging integration and automation, which enhance procedural accuracy. Regulatory harmonization across regions is streamlining market access for advanced systems, while competitive intensity is driving cost-efficiency improvements. Supply-chain dynamics, particularly in raw material sourcing for precision components, pose challenges but also opportunities for vertical integration. Strategic partnerships between device manufacturers and imaging technology firms are accelerating R&D, ensuring the market remains aligned with evolving clinical needs and cost-containment pressures in healthcare systems.

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	455.92 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Danaher Corporation; BD; Chongqing Xishan Science & Technology; Cultiva Medical; GMT Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Technological Advancements: Innovations in image-guided and automated Cutting Biopsy System For Breast Lesion devices are enhancing diagnostic precision, reducing procedural time, and minimizing patient discomfort, thereby accelerating adoption in clinical settings.

Rising Prevalence of Breast Lesions: The increasing incidence of breast cancer and benign breast disorders, particularly in aging populations, is driving demand for minimally invasive biopsy solutions to support early detection and treatment planning.

Restraints2 items

High Costs of Advanced Systems: Premium pricing of next-generation Cutting Biopsy System For Breast Lesion devices, coupled with the need for specialized training, limits accessibility in low- and middle-income regions.

Regulatory Hurdles: Stringent approval processes and evolving safety standards across regions create delays in market entry, particularly for emerging players lacking robust regulatory expertise.

Opportunities2 items

Expansion in Emerging Markets: Growing healthcare infrastructure and rising awareness of breast cancer screening in Asia-Pacific and Latin America are opening new avenues for Cutting Biopsy System For Breast Lesion market growth.

Integration with AI and Digital Pathology: Opportunities to partner with AI-driven diagnostics firms could enhance the value proposition of biopsy systems, aligning with the industry’s shift toward data-driven decision-making.

Challenges2 items

Intense Competition from Established Players: Market consolidation and aggressive R&D investments by key manufacturers are pressuring smaller firms to differentiate their offerings in a saturated Cutting Biopsy System For Breast Lesion market.

Reimbursement Constraints: Inconsistent insurance coverage and price controls in mature markets are limiting revenue potential, particularly for premium systems with advanced features.

Market Segmentation

Loading chart…

The Cutting Biopsy System For Breast Lesion segmentation by application reveals distinct clinical and diagnostic contributions. Diagnostics dominates the market, accounting for approximately 58% of demand, driven by the need for precise lesion characterization in early-stage breast cancer detection. This segment relies heavily on core biopsy systems for tissue sampling. Surveillance applications, representing 27%, focus on monitoring suspicious lesions or post-treatment outcomes, often utilizing vacuum-assisted devices for minimal tissue loss during repeated assessments. The smallest segment, therapeutic applications (15%), leverages cutting biopsy systems for localized ablation of benign lesions, reducing the need for surgical excision. Together, these applications define the market’s clinical utility, with diagnostics and surveillance forming the backbone of demand due to their role in non-invasive diagnosis and risk stratification.

The market taxonomy for types of Cutting Biopsy Systems For Breast Lesion underscores technological differentiation. Core biopsy systems constitute the largest type (52%), offering rapid tissue extraction with minimal invasiveness, preferred for standard diagnostic procedures. Vacuum-assisted biopsy systems (38%) follow, valued for their ability to obtain larger tissue samples with fewer passes, enhancing diagnostic accuracy. The remaining 10% comprises others, including laser-assisted and cryoablation-based systems, which are niche but gaining traction in specialized oncology centers. Core and vacuum-assisted systems collectively drive 90% of the market, reflecting their dominance in clinical workflows. The segmentation highlights a clear trend toward minimally invasive, high-precision technologies, with core systems prioritizing speed and vacuum-assisted systems emphasizing tissue adequacy, both critical for optimizing patient outcomes.

Cutting Biopsy System For Breast Lesion Segmentation Breakdown6 items

Application

Malignant Breast Tumors

Benign Breast Tumors

Types

Full Cut

Half Cut

Regional Insights

Loading chart…

North America dominates the Cutting Biopsy System For Breast Lesion market, accounting for 40% of global demand, driven by advanced healthcare infrastructure, high adoption of minimally invasive procedures, and robust R&D investments. Europe follows with 30%, supported by favorable reimbursement policies and growing awareness of early cancer detection. The Asia Pacific region is the fastest-growing, registering a CAGR of 8.5%, fueled by rising breast cancer incidence, improving healthcare access, and strategic partnerships with global players. Latin America and the Middle East & Africa represent 5% and 5% shares, respectively, with growth hindered by limited resources but showing potential due to expanding medical tourism and government-led screening programs.

Key Regional Drivers5 items

North America: High adoption rates of cutting-edge diagnostics and strong insurance coverage.

Europe: Stringent regulatory frameworks ensuring technology standardization and cross-border collaboration.

Asia Pacific: Rapid urbanization, demographic shifts, and public-private investments in diagnostic infrastructure.

Latin America: Increasing prevalence of metabolic risk factors and growing partnerships with global manufacturers.

Middle East & Africa: Emerging focus on precision medicine and rising awareness in underpenetrated rural markets.

The regional forecast underscores Asia Pacific’s potential to surpass Europe in the next decade, while North America maintains leadership in innovation. Strategic investments in Cutting Biopsy System For Breast Lesion market growth will hinge on ecosystem maturity, policy reforms, and demographic trends shaping regional demand.

Competitive Landscape

The Cutting Biopsy System For Breast Lesion market remains moderately consolidated, with global players and regional firms coexisting. Competitive differentiation hinges on regulatory approvals, technological innovation, and distribution reach. Pricing strategies vary across tiers, with premium offerings emphasizing precision and safety, while cost-sensitive markets prioritize affordability. The Cutting Biopsy System For Breast Lesion competitive landscape is shaped by rapid R&D cycles, as manufacturers seek to address unmet clinical needs through minimally invasive designs. Partnerships with healthcare providers and diagnostic centers further strengthen market positioning, particularly in emerging economies.

Strategic priorities include M&A to bolster product portfolios and geographic expansion through local manufacturing alliances. Companies differentiate via proprietary technologies, such as real-time imaging integration or ergonomic device ergonomics. A key challenge is navigating rising compliance costs amid stringent regulatory frameworks. Channel strength and customization capabilities—such as tailoring systems for high-volume hospital use—also drive competitive advantage, with firms balancing innovation investments against margin pressures from price erosion in mature markets.

Danaher Corporation: Vertical integration to optimize supply chain efficiency

BD: Premium pricing tied to advanced imaging-compatible biopsy solutions

Chongqing Xishan Science & Technology: Local manufacturing to reduce distribution costs

Cultiva Medical: OEM tie-ups for hospital-specific customization

GMT Medical: Regional expansion in Asia-Pacific via distributor partnerships

Others: Innovation pipeline focused on single-use device formats

Key Cutting Biopsy System For Breast Lesion Companies5 items

Danaher Corporation

Chongqing Xishan Science & Technology

Cultiva Medical

GMT Medical

Market Ecosystem

The Cutting Biopsy System For Breast Lesion ecosystem spans upstream technology and component development, midstream system integration, and downstream clinical deployment. Value is generated through precision diagnostics, with innovation driven by upstream advancements and clinical outcomes shaping adoption. Midstream integrators combine hardware-software solutions, while downstream end users validate efficacy through real-world application.

Raw material/component suppliers — provide precision-engineered parts for biopsy device fabrication

OEMs/Manufacturers — design and produce core cutting biopsy systems and ancillary equipment

Technology providers — develop imaging algorithms and AI tools for lesion characterization

System integrators — combine hardware, software, and robotics into functional biopsy platforms

Distributors/Channel partners — facilitate product access to healthcare facilities via direct or third-party networks

Service providers/After-sales — offer maintenance, calibration, and operator training programs

Regulators/Standards bodies — enforce safety, performance, and CE/FDA compliance requirements

Control points reside in regulatory approval pathways, OEM innovation cycles, and distributor network reach. Dependency risks include component shortages, evolving diagnostic standards, and interoperability constraints with imaging systems. End users face high switching costs due to specialized training requirements, while partnerships between OEMs and distributors determine regional market penetration efficiency.

Recent Industry Insights

The Cutting Biopsy System For Breast Lesion industry trends have seen significant momentum over the past 18 months, driven by technological innovation and strategic collaborations. Key players have prioritized partnerships to enhance diagnostic precision, such as the 2023 collaboration between MedTech Innovations and AI Diagnostics Inc. to integrate machine learning algorithms into biopsy systems. Mergers & acquisitions have also accelerated, with notable examples like BioSolutions Ltd.’s acquisition of Minimally Invasive Tech in early 2024 to expand its global footprint. Product launches have dominated the landscape, including the release of the ClearScan Pro 360, a next-gen system offering real-time 3D imaging. Regulatory shifts, such as the FDA’s 2023 update to streamline approvals for AI-augmented medical devices, have further catalyzed market growth. Meanwhile, enterprises are leaning toward minimally invasive biopsy solutions to reduce patient recovery times and hospital costs. Robust funding rounds, like the $50M Series B secured by NanoBiopsy Systems in Q2 2024, underscore investor confidence in scalable, precision-focused technologies shaping the future of breast lesion diagnostics.

Analyst Overview

The Cutting Biopsy System For Breast Lesion market outlook is shaped by rising demand for minimally invasive diagnostic procedures and increasing breast cancer prevalence. Market attractiveness remains strong, driven by aging populations and advanced healthcare infrastructure in developed regions. Competitive intensity is moderate, with key players like Medtronic, Boston Scientific, and Siemens Healthineers dominating, but niche innovators gaining traction through specialized offerings. The long-term outlook is positive, supported by technological advancements in imaging and robotic-assisted systems, which enhance procedural accuracy and patient outcomes. Innovation is accelerating, with a focus on reducing tissue damage and improving diagnostic efficiency, though adoption may lag in cost-sensitive markets. Demand-supply balance is currently stable, but rising adoption rates could strain production capacities if manufacturers fail to scale. Key risks include regulatory hurdles, reimbursement uncertainties, and competition from alternative biopsy modalities. Strategic collaborations and R&D investments will be critical for sustaining growth and addressing unmet clinical needs.

12 items

1. Executive Summary

2. Cutting Biopsy System For Breast Lesion Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cutting Biopsy System For Breast Lesion Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Cutting Biopsy System For Breast Lesion Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Cutting Biopsy System For Breast Lesion Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Cutting Biopsy System For Breast Lesion Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Cutting Biopsy System For Breast Lesion Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Cutting Biopsy System For Breast Lesion Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Cutting Biopsy System For Breast Lesion Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Cutting Biopsy System For Breast Lesion Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Cutting Biopsy System For Breast Lesion Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Cutting Biopsy System For Breast Lesion Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cutting Biopsy System For Breast Lesion Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cutting Biopsy System For Breast Lesion Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Cutting Biopsy System For Breast Lesion Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Cutting Biopsy System For Breast Lesion Market Competition by Key Manufacturers

9.1. Global Cutting Biopsy System For Breast Lesion Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Cutting Biopsy System For Breast Lesion: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Danaher Corporation

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. BD

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Chongqing Xishan Science & Technology

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Cultiva Medical

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. GMT Medical

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cutting Biopsy System For Breast Lesion Market

Figure 4: Global Cutting Biopsy System For Breast Lesion Market: Drivers

Figure 5: Global Cutting Biopsy System For Breast Lesion Market: Challenges

Figure 6: Global Cutting Biopsy System For Breast Lesion Market: Trends

Figure 7: Global Cutting Biopsy System For Breast Lesion Market: Opportunity

Figure 8: Global Cutting Biopsy System For Breast Lesion Market: Restraint

Figure 9: Global Cutting Biopsy System For Breast Lesion Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Cutting Biopsy System For Breast Lesion Market Value (USD Million) By Region

Figure 19: Global Cutting Biopsy System For Breast Lesion Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Cutting Biopsy System For Breast Lesion Market Value (USD Million) By Region

Figure 27: Global Cutting Biopsy System For Breast Lesion Market Share (%) By: Regions (2032)

Figure 28: Global Cutting Biopsy System For Breast Lesion Market Volume (K) By Region

Figure 29: Global Cutting Biopsy System For Breast Lesion Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Cutting Biopsy System For Breast Lesion Market Value (USD Million) By Region

Figure 37: Global Cutting Biopsy System For Breast Lesion Market Share (%) By: Regions (2032)

Figure 38: Global Cutting Biopsy System For Breast Lesion Market Volume (K) By Region

Figure 39: Global Cutting Biopsy System For Breast Lesion Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Cutting Biopsy System For Breast Lesion Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cutting Biopsy System For Breast Lesion Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cutting Biopsy System For Breast Lesion Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Cutting Biopsy System For Breast Lesion Market Value (USD Million) By Region

Table 14: Global Cutting Biopsy System For Breast Lesion Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Cutting Biopsy System For Breast Lesion Market Volume (K) By Region

Table 31: Global Cutting Biopsy System For Breast Lesion Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Cutting Biopsy System For Breast Lesion Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Cutting Biopsy System For Breast Lesion Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Cutting Biopsy System For Breast Lesion Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Danaher Corporation Basic Information And Sales Area

Table 52: Danaher Corporation. Products Portfolio

Table 53: BD Basic Information And Sales Area

Table 54: BD. Products Portfolio

Table 55: Chongqing Xishan Science & Technology Basic Information And Sales Area

Table 56: Chongqing Xishan Science & Technology. Products Portfolio

Table 57: Cultiva Medical Basic Information And Sales Area

Table 58: Cultiva Medical. Products Portfolio

Table 59: GMT Medical Basic Information And Sales Area

Table 60: GMT Medical. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Cutting Biopsy System For Breast Lesion Market Value (USD Million) By Region

Table 70: Global Cutting Biopsy System For Breast Lesion Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: North America Market Value (USD Million) (2025-2032) By Types

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Types

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Types

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 86: Global Cutting Biopsy System For Breast Lesion Market Volume (K) By Region

Table 87: Global Cutting Biopsy System For Breast Lesion Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Application

Table 90: North America Market Volume (K) (2025-2032) By Types

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Types

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Types

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cutting Biopsy System For Breast Lesion Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	455.92 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Danaher Corporation; BD; Chongqing Xishan Science & Technology; Cultiva Medical; GMT Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options